Wyeth to close Premarin plant, declining sales to blame

Share this article:
Wyeth said that it plans to cease operations at its Premarin (conjugated estrogens tablets) manufacturing plant in Rouses Point, N.Y., because of declining sales of the hormone-replacement drug.
In a news release, Wyeth said it plans to phase out manufacturing at the plant and halt all operations by late 2008. Staff reductions will begin in 2006 and extend over the next three years.
Sales of post-menopausal hormone therapies have been significantly hurt by studies showing women who take hormones after menopause have a greater risk of breast cancer, stroke, heart attack, incontinence and dementia.
A Wyeth spokesman told The Wall Street Journal the plant employs 1,200 workers.
 The spokesman couldn't immediately estimate the number of workers expected to leave the company or the anticipated costs of the move, according to the Journal report. 
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.